For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON ...

1 Berkshire Hathaway (Class A) remains the most expensive stock globally at $730,000 per share in 2025. 2 Lindt & Sprüngli AG ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Analysts at William Blair say dapiglutide’s 11.6% weight reduction at 28 weeks could still be better, given that Zealand’s ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and Alkermes (ALKS – Research Report). Confident I ...

“Steven brings a unique 360-degree perspective on global drug development gained from a career at major pharma companies, CROs and the FDA,” said Adam Steensberg, Chief Executive Officer, Zealand ...

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or ...

Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...

Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational ...